4.5 Article

Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity

期刊

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IGC.0000000000000697

关键词

Mesothelium; MHC; Peritoneum; T cell; Engulf; Inflammation

资金

  1. St George's, University of London
  2. Medical Research Council [MR/K019732/2, MR/K019732/1] Funding Source: researchfish
  3. MRC [MR/K019732/2] Funding Source: UKRI

向作者/读者索取更多资源

Mesothelial cells lining the peritoneal cavity are strategically positioned to respond to and counter intraperitoneal infections, cancer cells, and other challenges. We have investigated human peritoneal mesothelial cells (HPMCs) for phagocytic activity, expression of surface Major Histocompatibility Complex (MHC) class II and accessory molecules involved in antigen presentation, and the ability to present recall antigens to T cells. Phagocytosis of dextran, latex beads, and Escherichia coli was observed by flow cytometry, and internalization was visualized using confocal and electron microscopy. Flow cytometry and/or cellular enzyme-linked immunosorbent assay showed constitutive expression of ICAM-1, LFA-3, and B7-1, but not B7-2 or MHC class II. Interferon-gamma induced MHC II and ICAM-1 expression in a dose-and time-dependent manner. Importantly, HPMCs induced autologous CD3(+) T-lymphocyte proliferation (H-3 incorporation) after pulse with recall antigen. Human peritoneal mesothelial cells equipped with phagocytic and antigen-presenting machinery are anticipated to have an integral role in intraperitoneal immune surveillance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Jonathan S. Cebon, Martin Gore, John F. Thompson, Ian D. Davis, Grant A. McArthur, Euan Walpole, Mark Smithers, Vincenzo Cerundolo, P. Rod Dunbar, Duncan MacGregor, Cyril Fisher, Michael Millward, Paul Nathan, Michael P. N. Findlay, Peter Hersey, T. R. Jeffry Evans, Christian Hermann Ottensmeier, Jeremy Marsden, Angus G. Dalgleish, Pippa G. Corrie, Marples Maria, Margaret Brimble, Geoff Williams, Sintia Winkler, Heather M. Jackson, Liliana Endo-Munoz, Candani S. A. Tutuka, Ralph Venhaus, Lloyd J. Old, Dennis Haack, Eugene Maraskovsky, Andreas Behren, Weisan Chen

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Oncology

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells

P. L. Smith, Y. Yogaratnam, M. Samad, S. Kasow, A. G. Dalgleish

Summary: Chemotherapy for advanced pancreatic cancer is limited in efficacy due to difficulty in treating established tumors and tumor resistance. This study investigated the impact of combining Gemcitabine with immune modulatory chemotherapies on the immunogenicity of pancreatic tumor cells and T-cell responses, showing both additive and inhibitory effects on immune recognition markers. The findings highlight complex interactions in designing chemo-immunogenic combinations for use with immunotherapy.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

Article Immunology

The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for Vδ2+ γδ T cells in the modulation of immune response to tumour?

Emma L. Sparrow, Daniel W. Fowler, Joe Fenn, Jonathan Caron, John Copier, Angus G. Dalgleish, Mark D. Bodman-Smith

IMMUNOLOGY (2020)

Article Oncology

The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents

Andrew M. Gravett, Jayne L. Dennis, Angus G. Dalgleish, John Copier, Wai M. Liu

ONCOLOGY LETTERS (2020)

Review Medicine, Research & Experimental

The immuno-oncological implications of insulin

Gustav van Niekerk, Angus G. Dalgleish, Fourie Joubert, Annie Joubert, Anna-Mart Engelbrecht

Summary: Insulin regulates immune cell phenotypes through the PI3K/Akt/mTOR pathway, potentially impacting ICB therapy; Insulin interacts with immune pathways such as JAK/STAT, and is regulated by PD-1 and CTLA-4.

LIFE SCIENCES (2021)

Review Oncology

Naltrexone at low doses (LDN) and its relevance to cancer therapy

Wai M. Liu, Angus G. Dalgleish

Summary: Considering the increase in anecdotal reports, LDN shows potential in cancer treatment through its effects on receptors, immune function, and signaling pathways involved in cancer cell control. Clinical trials, especially in combination with certain chemotherapy, are recommended.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Article Biotechnology & Applied Microbiology

Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2

Katarzyna Piadel, Amin Haybatollahi, Angus George Dalgleish, Peter Lawrence Smith

Summary: The study investigates alternative vaccine strategies to broaden T-cell responses and provide cross-immunity against SARS-CoV-2 variants and future coronavirus outbreaks. Highly conserved peptides containing immunogenic epitopes were synthesized and demonstrated antigenicity against T-cells from individuals with previous SARS-CoV-2 infection.

JOURNAL OF GENERAL VIROLOGY (2022)

Article Oncology

Combination of cannabidiol with low-dose naltrexone increases the anticancer action of chemotherapy in vitro and in vivo

Wai M. Liu, Nadine K. Hall, Harry S. Y. Liu, Francis L. Hood, Angus G. Dalgleish

Summary: The combination of CBD and LDN, administered in a specific sequence, significantly reduces cancer cell numbers and enhances sensitivity to chemotherapy. This effect is also observed in a mouse model, with no significant toxicity.

ONCOLOGY REPORTS (2022)

Article Immunology

Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy

Peter Lawrence Smith, Katarzyna Piadel, Angus George Dalgleish

Summary: Cancer vaccination and immunotherapy have revolutionized cancer treatment, but only a minority of patients respond to this treatment and some cancers are resistant to it. CD4(+) and CD8(+) alpha beta T-cells play a crucial role in the anti-tumor immune response, but their function is often compromised in cancer patients.

VACCINES (2021)

Article Immunology

Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid

J. Fenn, L. A. Ridgley, A. White, C. Sarfas, M. Dennis, A. Dalgleish, R. Reljic, S. Sharpe, M. Bodman-Smith

Summary: This study demonstrates that Bacillus Calmette-Guerin (BCG) can expand V delta 2(+) T cells and enhance their cytotoxicity against tumor cells, suggesting its potential in enhancing anti-tumor responses. Compared to zoledronic acid (ZA) expanded cells, BCG-expanded cells exhibit a more diverse range of cytokine production and lower upregulation of exhaustion marker CD57. These findings highlight the potential of BCG treatment in potentiating anti-tumor V delta 2(+) T cell responses.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

Editorial Material Oncology

Cancer vaccines

John T. Schiller, Douglas R. Lowy

Summary: Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, this article revisits the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and provide insights into the clinical development progress and challenges that need to be overcome for wide implementation.

CANCER CELL (2022)

Article Oncology

The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients

Angus G. Dalgleish, Wai M. Liu

Summary: This study described the use of a novel immunotherapy, IMM-101, in combination with conventional treatments in patients with prostate cancer. The results showed that IMM-101 treatment, along with an anti-inflammatory agent, led to clinical improvements and reduction in prostate-specific antigen levels in some patients.

ONCOLOGY LETTERS (2022)

Editorial Material Oncology

Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope

Christine Galustian, Angus Dalgleish, Mark Bodman-Smith, Sergei Kusmartsev, Prokar Dasgupta

FRONTIERS IN ONCOLOGY (2022)

Article Immunology

Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance

Laura A. Ridgley, Jonathan Caron, Angus Dalgleish, Mark Bodman-Smith

Summary: The expression of activatory and inhibitory receptors on V gamma 9V delta 2 T-cells was assessed to explore the potential regulation of their activity. The results showed that V gamma 9V delta 2 T-cells expressed high levels of activatory markers and variable levels of inhibitory receptors, which were upregulated upon stimulation. However, immune checkpoint blockade had no effect on the cytotoxic capacity or cytokine production of V delta 2+ T-cells when cultured with tumor cells expressing cognate ligands.

FRONTIERS IN IMMUNOLOGY (2023)

暂无数据